A Phase 1/2 interventional study of Influenza Vaccine 1 and mRNA-1083.1 in SARS-CoV-2 and Influenza, sponsored by ModernaTX, Inc.. Completed at 69 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Influenza, Human by Moderna, Inc. — 2 open to participants now, 3 under way, 1 of them phase 3. Influenza, Human · Moderna, Inc..
Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 8th largest by enrollment, is one of 6 that started in 2023, is one of 6 in phase 1/2, and was the 13th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →2 of the 23 studies in Influenza, Human by Moderna, Inc. are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
By country, each count listing its studies:
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 7 · Phase 4 1
First in 2015; this study’s year is marked. 6 started in 2023.
This study's enrollment of 1,758 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 885 across the 23 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
2 of the studies in Influenza, Human by Moderna, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496450Phase 3ModernaTX, Inc.A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | 2027-01-28 |
| NCT07884175ModernaTX, Inc.A Study of Updated mRNA Seasonal Influenza Vaccines | 2026-12-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Influenza, Human by Moderna, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults.
The purpose of Part 2 of this study is to generate safety and immunogenicity data for additional mRNA-1083 compositions and dose levels in young adults ≥18 years and \<50 years of age.
Part 1: Participants will be enrolled into 1 of 2 age cohorts: Cohort A for adults ≥65 to \<80 years of age or Cohort B for adults ≥18 to \<65 year of age. In Cohort A, approximately 600 participants will be randomized (in equal allocation ratio) into the investigational treatment arms, stratified by influenza vaccine status in the most recent influenza season (received or not received since September 2022). In Cohort B, approximately 624 participants will be randomized (in equal allocation ratio) into the investigational treatment arms, stratified by 2 age groups: ≥18 to \<50 years and ≥50 to \<65 years of age and by influenza vaccine status in the most recent influenza season (received or not received since September 2022).
Part 2: Approximately, 520 participants between ≥18 to \<50 years of age will be randomized (in equal allocation ratio) into the investigational treatment arms, stratified by influenza vaccine status in the most recent influenza season (received or not received since Sept 2023).
Key Inclusion Criteria:
Part 1 (Phase 1/2)
Part 2 (Phase 2 Extension)
Key Exclusion Criteria:
Part 1 (Phase 1/2) and Part 2 (Phase 2 Extension)
Part 2 (Phase 2 Extension) Only
Note: Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single intramuscular (IM) injection of mRNA-1083.1 at Dose Level B on Day 1.
Biological: mRNA-1083.1
Participants will receive single IM injection of mRNA-1083.1 at Dose Level C on Day 1.
Biological: mRNA-1083.1
Participants will receive single IM injection of mRNA-1083.2 at Dose Level A on Day 1.
Biological: mRNA-1083.2
Participants will receive single IM injection of mRNA-1083.2 at Dose Level B on Day 1.
Biological: mRNA-1083.2
Participants will receive single IM injection of mRNA-1083.2 at Dose Level C on Day 1.
Biological: mRNA-1083.2
Participants will receive single IM injection of mRNA-1083.3 on Day 1.
Biological: mRNA-1083.3
Participants will receive single IM injection of Investigational Influenza Vaccine 1 on Day 1.
Biological: Investigational Influenza Vaccine 1
Participants will receive single IM injection of Investigational COVID-19 Vaccine 1 on Day 1.
Biological: Investigational COVID-19 Vaccine 1
Participants will receive single IM injection of COVID-19 Vaccine 1 on Day 1.
Biological: COVID-19 Vaccine 1
Participants will receive single IM injection of Investigational Influenza Vaccine 2 on Day 1.
Biological: Investigational Influenza Vaccine 2
Participants will receive single IM injection of Influenza Vaccine 1 on Day 1.
Biological: Influenza Vaccine 1
Participants will receive single IM injection of Influenza Vaccine 2 on Day 1.
Biological: Influenza Vaccine 2
Participants will receive single IM injection of mRNA-1083.1 at Dose Level A on Day 1.
Biological: mRNA-1083.1
Participants will receive single IM injection of mRNA-1083.1 at Dose Level B on Day 1.
Biological: mRNA-1083.1
Participants will receive single IM injection of mRNA-1083.1 at Dose Level C on Day 1.
Biological: mRNA-1083.1
Participants will receive single IM injection of mRNA-1083.2 at Dose Level A on Day 1.
Biological: mRNA-1083.2
Participants will receive single IM injection of mRNA-1083.2 at Dose Level B on Day 1.
Biological: mRNA-1083.2
Participants will receive single IM injection of mRNA-1083.2 at Dose Level C on Day 1.
Biological: mRNA-1083.2
Participants will receive single IM injection of mRNA-1083.3 on Day 1.
Biological: mRNA-1083.3
Participants will receive single IM injection of Investigational Influenza Vaccine 1 on Day 1.
Biological: Investigational Influenza Vaccine 1
Participants will receive single IM injection of Investigational COVID-19 Vaccine 1 on Day 1.
Biological: Investigational COVID-19 Vaccine 1
Participants will receive single IM injection of COVID-19 Vaccine 1 on Day 1.
Biological: COVID-19 Vaccine 1
Participants will receive single IM injection of Investigational Influenza Vaccine 2 on Day 1.
Biological: Investigational Influenza Vaccine 2
Participants will receive single IM injection of Influenza Vaccine 1 on Day 1.
Biological: Influenza Vaccine 1
Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level A on Day 1.
Biological: mRNA-1083
Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level A on Day 1.
Biological: mRNA-1083
Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level B on Day 1.
Biological: mRNA-1083
Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level B on Day 1.
Biological: mRNA-1083
Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level C on Day 1.
Biological: mRNA-1083
Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level C on Day 1.
Biological: mRNA-1083
Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level D on Day 1.
Biological: mRNA-1083
Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level D on Day 1.
Biological: mRNA-1083
Participants will receive single IM injection of Investigational Influenza Vaccine 1 at Dose Level A on Day 1.
Biological: Investigational Influenza Vaccine 1
Participants will receive single IM injection of Investigational Influenza Vaccine 1 at Dose Level B on Day 1.
Biological: Investigational Influenza Vaccine 1
Participants will receive single IM injection of Investigational COVID-19 Vaccine 2 on Day 1.
Biological: Investigational COVID-19 Vaccine 2
Participants will receive single IM injection of COVID-19 Vaccine 2 on Day 1.
Biological: COVID-19 Vaccine 2
Participants will receive single IM injection of Influenza Vaccine 1 on Day 1.
Biological: Influenza Vaccine 1
quadrivalent seasonal influenza vaccine
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
quadrivalent seasonal influenza vaccine
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs (local and systemic) were reported by participants an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills.
Time frame: Up to 7 days after study injection
Parts 1 and 2: Number of Participants With Unsolicited Adverse Events (AEs) and Severe AEs
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Severity for all unsolicited AEs was determined by the Investigator based upon medical judgment and graded as Mild, Moderate or Severe. Number of participants with unsolicited AEs (SAEs and non-serious AEs) and severe AEs up to 28 days post-vaccination are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 28 days after study injection
Parts 1 and 2: Number of Participants With Unsolicited Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs were protocol-defined medical concepts. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site. Number of participants with SAEs, AESIs, MAAEs, and AEs leading to study discontinuation up to Day 181 are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 through Day 181
Part 2: Geometric Mean Titer (GMT) of Antibodies for Influenza at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than the upper limit of quantification (ULOQ) were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values for geometric mean (GM) titer, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
Time frame: Day 29
Part 2: GM Concentration of Antibodies for SARS-CoV-2 at Day 29, as Measured by Pseudovirus Neutralization Assay (PsVNA)
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 arbitrary units (AU)/milliliter (mL) for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM concentration, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
Time frame: Day 29
Part 2: Geometric Mean Fold-Rise (GMFR) of Antibodies for Influenza at Day 29, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
Time frame: Day 29
Part 2: GMFR of Antibodies for SARS-CoV-2 at Day 29, as Measured by PsVNA
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
Time frame: Day 29
Part 2: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \<1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer. Arms based on the applicable vaccine for this Outcome Measure.
Time frame: Baseline to Day 29
Part 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 \* LLOQ if Baseline neutralizing antibody (nAb) level was \< LLOQ, or ≥4-fold rise if Baseline nAb level was ≥ LLOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. Arms based on the applicable vaccine for this Outcome Measure.
Time frame: Baseline to Day 29
Part 1: GMT of Antibodies for Influenza, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 10 and ULOQ = 640 for Influenza A H1N1 and Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 320 for Influenza B/ Victoria, and LLOQ = 10 and ULOQ = 640 for Influenza B/Yamagata antibody. 95% CI was calculated based on t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
Time frame: Baseline (Day 1), Day 29, and Day 181
Part 1: GMT of Antibodies for SARS-CoV-2, as Measured by PsVNA
SARS-CoV-2 strain included BA.4/5 and D614G antibody. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 53 and ULOQ = 71376 for SARS-CoV-2 BA.4/5 antibody and LLOQ = 74.1 and ULOQ = 184317 for SARS-CoV-2 D614G antibody. 95% CI was calculated based on t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
Time frame: Baseline (Day 1), Day 29, and Day 181
Part 1: GMFR of Antibodies for Influenza, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 10 and ULOQ = 640 for Influenza A H1N1 and Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 320 for Influenza B/Victoria, and LLOQ = 10 and ULOQ = 640 for Influenza B/Yamagata antibody. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
Time frame: Day 29 and Day 181
Part 1: GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA
SARS-CoV-2 strain included BA.4/5 and D614G antibody. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 53 and ULOQ = 71376 for SARS-CoV-2 BA.4/5 antibody and LLOQ = 74.1 and ULOQ = 184317 for SARS-CoV-2 D614G antibody. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
Time frame: Day 29 and Day 181
Part 1: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \< 1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post vaccination HAI antibody titer. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
Time frame: Baseline (Day 1) to Day 29, and Day 181
Part 1: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA
SARS-CoV-2 strain included BA.4/5 and D614G antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 x LLOQ if baseline nAb level was \<LLOQ, or ≥4 fold rise if baseline nAb level was ≥LLOQ. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
Time frame: Baseline (Day 1) to Day 29, and Day 181
Part 2: GMT of Antibodies for Influenza, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
Time frame: Baseline (Day 1), Day 181
Part 2: GM Concentration of Antibodies for SARS-CoV-2, as Measured by PsVNA
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 arbitrary units (AU)/milliliter (mL) for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM concentration, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
Time frame: Baseline (Day 1), Day 181
Part 2: GMFR of Antibodies for Influenza, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ replaced by 0.5 \* LLOQ. Values greater than ULOQ converted to ULOQ. LLOQ= 10, ULOQ= 3620 for Influenza A H1N1, LLOQ= 10, ULOQ= 5120 for Influenza A H3N2, LLOQ= 10, ULOQ= 1356 for Influenza B/Victoria-lineage, and LLOQ= 10, ULOQ= 1280 for Influenza B/Yamagata-lineage. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
Time frame: Day 181
Part 2: GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
Time frame: Day 181
Part 2: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \<1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer. PP Set included all randomized participants who received the study intervention, complied with the injection schedule, complied with the timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected the immune response.
Time frame: Baseline (Day 1) to Day 181
Part 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 \* LLOQ if Baseline nAb level was \< LLOQ, or ≥4-fold rise if Baseline nAb level was ≥ LLOQ. PP Set included all randomized participants who received the study intervention, complied with the injection schedule, complied with the timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected the immune response.
Time frame: Baseline (Day 1) to Day 181
| Milestone | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 54 | 53 | 54 | 53 | 54 | 52 | 52 | 33 | 54 | 54 | 33 | 53 | 52 | 56 | 56 | 56 | 55 | 56 | 56 | 37 | 55 | 56 | 38 | 56 | 41 | 40 | 40 | 42 | 40 | 40 | 42 | 42 | 41 | 40 | 40 | 40 | 42 |
| Received study injection | 54 | 53 | 54 | 51 | 54 | 52 | 51 | 33 | 54 | 54 | 33 | 53 | 52 | 55 | 55 | 53 | 55 | 55 | 56 | 37 | 55 | 55 | 38 | 54 | 40 | 39 | 40 | 42 | 40 | 40 | 42 | 41 | 41 | 40 | 40 | 40 | 42 |
| Safety set | 54 | 53 | 54 | 51 | 54 | 52 | 51 | 33 | 55 | 53 | 33 | 53 | 52 | 55 | 55 | 53 | 55 | 56 | 55 | 37 | 56 | 54 | 38 | 54 | 40 | 39 | 40 | 42 | 40 | 40 | 42 | 41 | 41 | 40 | 40 | 40 | 42 |
| Solicited safety set | 54 | 53 | 54 | 51 | 54 | 52 | 51 | 33 | 55 | 53 | 33 | 53 | 52 | 55 | 55 | 53 | 55 | 56 | 55 | 37 | 56 | 54 | 38 | 53 | 40 | 39 | 40 | 42 | 40 | 40 | 42 | 41 | 41 | 40 | 40 | 40 | 42 |
| Per protocol set | 51 | 50 | 50 | 45 | 51 | 49 | 50 | 30 | 53 | 51 | 31 | 50 | 50 | 48 | 52 | 50 | 53 | 51 | 53 | 36 | 50 | 52 | 38 | 51 | 38 | 38 | 37 | 40 | 38 | 39 | 42 | 40 | 39 | 40 | 38 | 33 | 42 |
| Full analysis set (fas) | 54 | 53 | 54 | 51 | 54 | 52 | 51 | 33 | 54 | 54 | 33 | 53 | 52 | 55 | 55 | 53 | 55 | 55 | 56 | 37 | 55 | 55 | 38 | 54 | 40 | 39 | 40 | 42 | 40 | 40 | 42 | 41 | 41 | 40 | 40 | 40 | 42 |
| Completed | 52 | 53 | 53 | 51 | 54 | 51 | 51 | 33 | 54 | 54 | 33 | 53 | 50 | 53 | 55 | 52 | 52 | 55 | 55 | 37 | 53 | 53 | 36 | 53 | 38 | 38 | 36 | 40 | 38 | 39 | 37 | 39 | 38 | 38 | 39 | 37 | 37 |
| Not completed | 2 | 0 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 4 | 3 | 1 | 1 | 0 | 2 | 3 | 2 | 3 | 3 | 2 | 4 | 2 | 2 | 1 | 5 | 3 | 3 | 2 | 1 | 3 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 2 | 1 | 4 | 1 | 2 | 1 | 5 | 0 | 3 | 2 | 1 | 3 | 4 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other than specified | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Solicited ARs (local and systemic) were reported by participants an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills.
| Participants | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | 32 | 36 | 37 | 43 | 42 | 31 | 44 | 26 | 42 | 46 | 29 | 46 | 33 | 49 | 51 | 46 | 41 | 47 | 50 | 34 | 46 | 51 | 38 | 47 | 32 | 32 | 39 | 40 | 34 | 34 | 39 | 37 | 38 | 33 | 34 | 37 | 39 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Severity for all unsolicited AEs was determined by the Investigator based upon medical judgment and graded as Mild, Moderate or Severe. Number of participants with unsolicited AEs (SAEs and non-serious AEs) and severe AEs up to 28 days post-vaccination are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unsolicited AEs | 5 | 9 | 7 | 5 | 7 | 9 | 7 | 2 | 6 | 6 | 5 | 8 | 5 | 11 | 8 | 9 | 8 | 11 | 6 | 6 | 6 | 8 | 8 | 5 | 5 | 3 | 6 | 4 | 4 | 4 | 3 | 3 | 6 | 5 | 4 | 5 | 8 |
| Severe AEs | 0 | 1 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs were protocol-defined medical concepts. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site. Number of participants with SAEs, AESIs, MAAEs, and AEs leading to study discontinuation up to Day 181 are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAEs | 2 | 2 | 1 | 1 | 2 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| AESIs | 3 | 1 | 2 | 0 | 2 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| MAAEs | 11 | 16 | 13 | 16 | 13 | 20 | 12 | 4 | 12 | 14 | 7 | 10 | 13 | 13 | 13 | 17 | 17 | 15 | 10 | 9 | 10 | 13 | 12 | 5 | 8 | 7 | 6 | 8 | 8 | 10 | 6 | 11 | 6 | 11 | 10 | 9 | 8 |
| AEs Leading to Study Discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than the upper limit of quantification (ULOQ) were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values for geometric mean (GM) titer, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
| titer | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 80.0 (50.3 to 127.2) | 105.1 (71.9 to 153.7) | 129.0 (86.2 to 193.1) | 73.9 (52.6 to 103.6) | 98.3 (71.3 to 135.5) | 111.2 (81.2 to 152.5) | 99.9 (69.6 to 143.4) | 85.7 (61.0 to 120.4) | 88.4 (64.3 to 121.5) | 71.2 (47.6 to 106.7) | 106.0 (73.3 to 153.2) |
| Influenza A H3N2 Antibody | 80.7 (60.9 to 107.0) | 96.0 (66.3 to 139.1) | 155.6 (111.4 to 217.3) | 65.8 (50.3 to 86.1) | 71.3 (53.9 to 94.2) | 105.6 (80.2 to 139.0) | 79.3 (59.5 to 105.7) | 62.2 (45.5 to 85.1) | 79.3 (61.8 to 101.7) | 75.2 (54.0 to 104.5) | 80.7 (64.5 to 100.8) |
| Influenza B/Victoria-lineage Antibody | 86.0 (67.7 to 109.2) | 80.7 (59.5 to 109.5) | 141.9 (100.3 to 200.8) | 75.8 (57.4 to 100.2) | 104.2 (81.1 to 133.8) | 108.4 (84.2 to 139.5) | 106.3 (76.4 to 147.9) | 98.5 (72.2 to 134.3) | 78.5 (61.3 to 100.6) | 75.9 (56.7 to 101.6) | 82.0 (63.8 to 105.5) |
| Influenza B/Yamagata-lineage Antibody | 140.8 (110.2 to 179.9) | 122.8 (99.2 to 151.9) | 179.0 (130.4 to 245.7) | 80.7 (64.1 to 101.7) | 101.6 (80.0 to 129.0) | 112.2 (87.8 to 143.3) | 112.2 (90.1 to 139.7) | 94.3 (69.6 to 127.9) | 118.3 (87.4 to 160.3) | 97.7 (74.8 to 127.5) | 98.3 (76.5 to 126.2) |
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 arbitrary units (AU)/milliliter (mL) for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM concentration, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
| AU/mL | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part 2: GM Concentration of Antibodies for SARS-CoV-2 at Day 29, as Measured by Pseudovirus Neutralization Assay (PsVNA) | 1567.0 (1134.6 to 2164.4) | 1939.7 (1366.0 to 2754.4) | 427.6 (302.9 to 603.7) | 901.0 (655.9 to 1237.6) | 882.0 (630.5 to 1233.9) | 1108.3 (801.9 to 1531.7) | 679.7 (451.4 to 1023.4) | 878.7 (640.1 to 1206.2) | 904.8 (576.5 to 1420.1) | 1083.7 (744.2 to 1578.3) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
| ratio | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 2.6 (1.8 to 3.9) | 3.5 (2.5 to 4.8) | 3.7 (2.6 to 5.2) | 1.8 (1.4 to 2.2) | 2.2 (1.7 to 2.8) | 2.7 (1.9 to 3.9) | 2.0 (1.6 to 2.5) | 1.9 (1.3 to 2.7) | 2.7 (2.0 to 3.7) | 2.3 (1.6 to 3.1) | 2.9 (2.2 to 3.7) |
| Influenza A H3N2 Antibody | 2.8 (2.2 to 3.7) | 2.6 (2.1 to 3.3) | 3.4 (2.5 to 4.6) | 1.8 (1.4 to 2.3) | 1.9 (1.6 to 2.4) | 2.3 (1.7 to 3.1) | 2.0 (1.5 to 2.7) | 1.7 (1.4 to 2.1) | 2.3 (1.9 to 2.7) | 1.8 (1.3 to 2.4) | 2.7 (2.2 to 3.3) |
| Influenza B/Victoria-lineage Antibody | 1.7 (1.4 to 2.1) | 2.0 (1.5 to 2.6) | 2.4 (1.7 to 3.2) | 1.4 (1.2 to 1.7) | 1.6 (1.3 to 1.9) | 1.7 (1.5 to 2.1) | 2.1 (1.7 to 2.6) | 1.5 (1.2 to 1.8) | 1.5 (1.3 to 1.7) | 1.5 (1.3 to 1.9) | 1.7 (1.4 to 2.1) |
| Influenza B/Yamagata-lineage Antibody | 1.7 (1.4 to 2.2) | 2.3 (1.8 to 2.8) | 2.1 (1.7 to 2.7) | 1.3 (1.1 to 1.5) | 1.4 (1.2 to 1.7) | 1.6 (1.3 to 2.0) | 1.6 (1.4 to 1.9) | 1.3 (1.1 to 1.6) | 1.6 (1.3 to 2.0) | 1.4 (1.2 to 1.8) | 1.6 (1.3 to 1.8) |
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
| ratio | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part 2: GMFR of Antibodies for SARS-CoV-2 at Day 29, as Measured by PsVNA | 5.4 (3.3 to 8.7) | 9.1 (5.4 to 15.2) | 3.3 (2.1 to 5.2) | 5.4 (3.5 to 8.1) | 4.4 (2.9 to 6.9) | 3.6 (2.5 to 5.1) | 4.5 (2.9 to 6.9) | 4.1 (2.9 to 6.0) | 7.1 (4.4 to 11.4) | 8.0 (5.4 to 11.7) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \<1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer. Arms based on the applicable vaccine for this Outcome Measure.
| percentage of participants | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 31.6 (17.5 to 48.7) | 50.0 (33.4 to 66.6) | 51.4 (34.4 to 68.1) | 17.9 (7.5 to 33.5) | 31.0 (17.6 to 47.1) | 30.0 (16.6 to 46.5) | 25.6 (13.0 to 42.1) | 17.5 (7.3 to 32.8) | 34.2 (19.6 to 51.4) | 30.3 (15.6 to 48.7) | 35.7 (21.6 to 52.0) |
| Influenza A H3N2 Antibody | 42.1 (26.3 to 59.2) | 36.8 (21.8 to 54.0) | 43.2 (27.1 to 60.5) | 12.8 (4.3 to 27.4) | 23.8 (12.1 to 39.5) | 27.5 (14.6 to 43.9) | 23.1 (11.1 to 39.3) | 15.0 (5.7 to 29.8) | 21.1 (9.6 to 37.3) | 21.2 (9.0 to 38.9) | 42.9 (27.7 to 59.0) |
| Influenza B/Victoria-lineage Antibody | 15.8 (6.0 to 31.3) | 15.8 (6.0 to 31.3) | 27.0 (13.8 to 44.1) | 7.7 (1.6 to 20.9) | 9.5 (2.7 to 22.6) | 12.5 (4.2 to 26.8) | 23.1 (11.1 to 39.3) | 12.5 (4.2 to 26.8) | 2.6 (0.1 to 13.8) | 9.1 (1.9 to 24.3) | 11.9 (4.0 to 25.6) |
| Influenza B/Yamagata-lineage Antibody | 21.1 (9.6 to 37.3) | 26.3 (13.4 to 43.1) | 27.0 (13.8 to 44.1) | 7.7 (1.6 to 20.9) | 9.5 (2.7 to 22.6) | 12.5 (4.2 to 26.8) | 7.7 (1.6 to 20.9) | 17.5 (7.3 to 32.8) | 13.2 (4.4 to 28.1) | 9.1 (1.9 to 24.3) | 4.8 (0.6 to 16.2) |
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 \* LLOQ if Baseline neutralizing antibody (nAb) level was \< LLOQ, or ≥4-fold rise if Baseline nAb level was ≥ LLOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. Arms based on the applicable vaccine for this Outcome Measure.
| percentage of participants | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA | 55.0 (38.5 to 70.7) | 57.9 (40.8 to 73.7) | 33.3 (19.1 to 50.2) | 52.4 (36.4 to 68.0) | 47.5 (31.5 to 63.9) | 33.3 (19.1 to 50.2) | 50.0 (33.8 to 66.2) | 44.7 (28.6 to 61.7) | 63.6 (45.1 to 79.6) | 69.0 (52.9 to 82.4) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 10 and ULOQ = 640 for Influenza A H1N1 and Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 320 for Influenza B/ Victoria, and LLOQ = 10 and ULOQ = 640 for Influenza B/Yamagata antibody. 95% CI was calculated based on t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
| titer | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody: Day 1 | 49.7 (40.4 to 61.1) | 47.5 (36.9 to 61.2) | 55.0 (42.3 to 71.6) | 55.7 (43.3 to 71.6) | 58.2 (46.3 to 73.1) | 41.4 (29.0 to 59.2) | 55.1 (41.1 to 73.9) | 53.1 (39.5 to 71.3) | 39.1 (29.7 to 51.6) | 57.7 (46.1 to 72.4) | 48.3 (38.5 to 60.6) | 61.8 (47.2 to 81.0) | 48.9 (38.8 to 61.7) | 51.4 (38.5 to 68.8) | 57.3 (45.6 to 72.0) | 59.4 (44.2 to 79.7) | 52.7 (40.8 to 68.2) | 58.5 (47.0 to 72.8) | 77.0 (55.9 to 106.1) | 58.5 (44.8 to 76.3) |
| Influenza A H1N1 Antibody: Day 29 | 78.4 (60.9 to 100.8) | 85.7 (62.9 to 116.8) | 108.5 (84.0 to 140.1) | 149.3 (107.5 to 207.3) | 95.8 (74.8 to 122.8) | 104.3 (69.4 to 156.8) | 106.0 (81.5 to 137.9) | 139.5 (99.9 to 194.9) | 82.7 (56.3 to 121.3) | 129.1 (99.9 to 166.8) | 114.0 (82.1 to 158.3) | 145.3 (105.1 to 200.9) | 138.2 (101.7 to 187.7) | 126.4 (98.3 to 162.5) | 120.8 (89.7 to 162.6) | 135.9 (101.5 to 181.9) | 177.6 (135.6 to 232.4) | 142.9 (115.1 to 177.3) | 196.7 (138.2 to 280.1) | 150.5 (115.0 to 197.0) |
| Influenza A H1N1 Antibody: Day 181 | 104.5 (80.1 to 136.3) | 104.7 (74.8 to 146.7) | 99.3 (74.0 to 133.3) | 148.1 (99.2 to 221.1) | 104.3 (77.6 to 140.3) | 145.6 (104.1 to 203.7) | 127.3 (96.2 to 168.5) | 135.3 (102.4 to 178.7) | 104.2 (73.7 to 147.2) | 140.2 (108.9 to 180.5) | 118.4 (88.4 to 158.7) | 140.6 (108.1 to 182.8) | 174.5 (137.5 to 221.5) | 134.5 (104.6 to 173.0) | 147.9 (113.0 to 193.5) | 157.9 (111.4 to 223.8) | 176.3 (134.6 to 230.8) | 132.5 (105.9 to 165.9) | 156.1 (114.5 to 212.9) | 161.2 (121.6 to 213.8) |
| Influenza A H3N2 Antibody: Day 1 | 34.4 (25.5 to 46.6) | 34.1 (26.5 to 43.9) | 38.9 (29.3 to 51.5) | 30.7 (23.0 to 41.0) | 43.1 (33.9 to 54.9) | 31.7 (22.4 to 44.8) | 29.0 (21.4 to 39.5) | 37.6 (27.4 to 51.5) | 39.6 (28.3 to 55.2) | 32.1 (24.0 to 43.0) | 27.5 (21.3 to 35.5) | 48.3 (34.7 to 67.3) | 43.9 (33.2 to 58.1) | 38.9 (29.9 to 50.6) | 30.0 (23.9 to 37.6) | 36.0 (26.1 to 49.7) | 32.0 (23.4 to 43.9) | 43.0 (31.3 to 59.2) | 34.8 (25.9 to 46.7) | 33.2 (25.3 to 43.4) |
| Influenza A H3N2 Antibody: Day 29 | 61.8 (45.6 to 83.8) | 67.7 (48.9 to 93.8) | 88.3 (65.7 to 118.6) | 113.2 (77.6 to 165.0) | 90.7 (65.6 to 125.2) | 119.8 (74.9 to 191.7) | 64.8 (47.8 to 87.9) | 103.4 (78.1 to 136.9) | 94.6 (63.8 to 140.2) | 100.6 (75.5 to 134.1) | 64.5 (45.8 to 90.9) | 111.5 (84.8 to 146.7) | 117.8 (83.2 to 166.6) | 105.6 (79.4 to 140.3) | 73.0 (52.9 to 100.8) | 104.8 (70.3 to 156.0) | 116.3 (84.2 to 160.6) | 107.2 (77.7 to 147.8) | 93.8 (66.2 to 132.9) | 110.8 (78.8 to 155.9) |
| Influenza A H3N2 Antibody: Day 181 | 85.1 (64.2 to 112.9) | 87.2 (63.2 to 120.3) | 116.9 (80.0 to 170.7) | 146.7 (99.3 to 216.9) | 129.8 (96.2 to 175.2) | 196.4 (125.1 to 308.5) | 91.5 (71.5 to 117.0) | 114.2 (81.4 to 160.2) | 107.2 (72.5 to 158.5) | 117.9 (87.1 to 159.6) | 83.2 (64.9 to 106.6) | 111.2 (87.2 to 141.9) | 140.0 (93.9 to 208.6) | 129.4 (99.5 to 168.4) | 102.1 (73.7 to 141.5) | 149.3 (95.1 to 234.2) | 120.8 (87.8 to 166.2) | 145.7 (111.0 to 191.2) | 111.7 (79.7 to 156.7) | 134.1 (98.6 to 182.3) |
| Influenza B/Victoria-lineage Antibody: Day 1 | 55.4 (41.3 to 74.3) | 49.2 (35.8 to 67.8) | 46.7 (34.0 to 64.2) | 46.8 (34.5 to 63.4) | 73.1 (56.4 to 94.7) | 52.2 (36.7 to 74.3) | 72.5 (56.2 to 93.7) | 55.0 (41.3 to 73.0) | 46.8 (32.5 to 67.3) | 69.6 (52.3 to 92.8) | 34.5 (25.7 to 46.4) | 33.1 (23.5 to 46.6) | 31.5 (23.3 to 42.6) | 37.6 (28.5 to 49.6) | 39.0 (29.2 to 52.0) | 34.3 (23.3 to 50.4) | 35.3 (25.1 to 49.5) | 36.9 (28.2 to 48.4) | 33.0 (24.7 to 44.1) | 39.4 (28.6 to 54.4) |
| Influenza B/Victoria-lineage Antibody: Day 29 | 100.7 (70.1 to 144.8) | 106.3 (72.7 to 155.3) | 88.3 (65.3 to 119.4) | 151.5 (120.5 to 190.5) | 141.2 (107.9 to 184.9) | 128.5 (82.0 to 201.3) | 148.0 (115.3 to 189.9) | 155.5 (121.1 to 199.6) | 152.9 (106.7 to 219.1) | 172.7 (131.9 to 226.0) | 83.4 (58.7 to 118.6) | 59.1 (44.7 to 78.2) | 83.8 (59.7 to 117.6) | 76.8 (59.5 to 99.1) | 96.7 (70.2 to 133.0) | 89.0 (62.1 to 127.7) | 76.1 (55.1 to 105.2) | 113.1 (82.1 to 155.9) | 91.2 (65.2 to 127.7) | 93.5 (67.1 to 130.3) |
| Influenza B/Victoria-lineage Antibody: Day 181 | 167.2 (113.6 to 246.2) | 128.2 (86.3 to 190.6) | 95.1 (68.6 to 131.9) | 139.9 (108.0 to 181.1) | 140.6 (106.9 to 184.8) | 178.8 (110.4 to 289.4) | 174.5 (136.2 to 223.6) | 142.5 (101.1 to 200.9) | 183.7 (122.6 to 275.4) | 185.7 (136.2 to 253.1) | 103.2 (77.5 to 137.4) | 81.3 (58.0 to 113.9) | 115.9 (82.1 to 163.6) | 115.9 (86.8 to 154.6) | 126.3 (97.6 to 163.5) | 82.2 (53.0 to 127.5) | 86.0 (64.1 to 115.4) | 93.8 (73.0 to 120.4) | 99.9 (64.2 to 155.6) | 112.3 (81.4 to 155.0) |
| Influenza B/Yamagata-lineage Antibody: Day 1 | 49.0 (36.9 to 65.2) | 56.5 (43.0 to 74.3) | 62.9 (46.5 to 85.0) | 52.7 (39.7 to 70.0) | 80.6 (65.0 to 99.9) | 63.5 (45.3 to 88.9) | 74.5 (57.2 to 96.9) | 56.5 (42.8 to 74.7) | 48.4 (33.1 to 70.7) | 90.6 (68.8 to 119.4) | 78.3 (62.4 to 98.3) | 94.1 (74.0 to 119.6) | 85.5 (66.5 to 110.0) | 100.1 (74.0 to 135.4) | 91.1 (67.9 to 122.2) | 81.6 (60.9 to 109.3) | 74.7 (57.8 to 96.5) | 88.5 (67.6 to 115.8) | 101.1 (71.0 to 143.9) | 84.0 (62.2 to 113.5) |
| Influenza B/Yamagata-lineage Antibody: Day 29 | 75.2 (56.2 to 100.7) | 110.0 (83.3 to 145.3) | 100.4 (75.9 to 132.8) | 108.1 (82.3 to 141.9) | 110.8 (86.9 to 141.3) | 101.9 (69.0 to 150.4) | 112.3 (83.3 to 151.5) | 98.7 (75.9 to 128.1) | 80.0 (56.5 to 113.3) | 145.2 (109.5 to 192.7) | 151.4 (108.7 to 210.8) | 165.9 (132.4 to 208.0) | 176.7 (129.5 to 241.3) | 185.0 (134.8 to 253.9) | 178.0 (139.7 to 226.7) | 145.3 (100.5 to 210.0) | 154.5 (118.2 to 202.0) | 181.5 (139.6 to 236.1) | 246.1 (175.8 to 344.6) | 154.7 (113.5 to 210.8) |
| Influenza B/Yamagata-lineage Antibody: Day 181 | 94.8 (65.4 to 137.4) | 112.0 (78.2 to 160.5) | 84.5 (56.5 to 126.4) | 98.9 (68.6 to 142.5) | 109.6 (80.9 to 148.4) | 109.6 (71.7 to 167.6) | 98.9 (74.0 to 132.3) | 98.1 (68.4 to 140.9) | 87.3 (53.2 to 143.1) | 121.9 (87.6 to 169.6) | 88.4 (66.6 to 117.3) | 91.8 (69.2 to 121.8) | 121.4 (89.6 to 164.5) | 129.8 (95.6 to 176.1) | 121.4 (91.5 to 161.0) | 75.7 (50.2 to 114.1) | 112.2 (78.5 to 160.4) | 95.2 (72.9 to 124.1) | 111.7 (76.6 to 162.9) | 88.4 (66.6 to 117.5) |
SARS-CoV-2 strain included BA.4/5 and D614G antibody. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 53 and ULOQ = 71376 for SARS-CoV-2 BA.4/5 antibody and LLOQ = 74.1 and ULOQ = 184317 for SARS-CoV-2 D614G antibody. 95% CI was calculated based on t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
| titer | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 BA.4/5 Antibody: Day 1 | 618.0 (403.0 to 947.9) | 574.1 (352.8 to 848.2) | 616.9 (367.1 to 1036.8) | 585.9 (314.7 to 1090.6) | 646.6 (408.8 to 1022.7) | 536.3 (329.5 to 872.7) | 1008.2 (616.1 to 1649.7) | 883.2 (584.9 to 1333.6) | 384.1 (251.4 to 586.8) | 469.8 (297.5 to 741.8) | 653.7 (442.5 to 965.8) | 440.5 (295.7 to 656.3) | 487.5 (283.4 to 838.4) | 469.1 (292.1 to 753.2) | 524.8 (361.7 to 761.5) | 301.8 (195.0 to 467.1) | 489.8 (320.9 to 747.7) |
| SARS-CoV-2 BA.4/5 Antibody: Day 29 | 4536.9 (3147.0 to 6540.8) | 5476.9 (3988.2 to 7521.5) | 4636.7 (3098.6 to 6938.3) | 5387.3 (3207.7 to 9047.8) | 3706.0 (2656.8 to 5169.4) | 3669.6 (2577.8 to 5223.8) | 5647.8 (4227.0 to 7546.2) | 4120.6 (3224.4 to 5265.8) | 2635.8 (1973.8 to 3519.9) | 4743.9 (3529.0 to 6377.1) | 4005.9 (3131.4 to 5124.5) | 3061.1 (2308.3 to 4059.2) | 3599.0 (2577.6 to 5025.1) | 3425.6 (2558.6 to 4586.4) | 4391.3 (3488.0 to 5528.4) | 3119.7 (2360.0 to 4124.0) | 3458.4 (2595.9 to 4607.5) |
| SARS-CoV-2 BA.4/5 Antibody: Day 181 | 1500.1 (977.6 to 2301.8) | 2524.4 (1588.3 to 4012.3) | 1793.9 (1145.8 to 2808.5) | 1851.8 (899.5 to 3812.3) | 1461.3 (945.9 to 2257.6) | 1552.5 (935.1 to 2577.6) | 2185.7 (1425.4 to 3351.4) | 1480.3 (980.2 to 2235.6) | 1443.0 (1049.6 to 1983.9) | 1972.1 (1305.9 to 2978.2) | 1595.9 (1167.3 to 2181.8) | 1225.0 (861.6 to 1741.6) | 1657.5 (999.9 to 2747.5) | 1413.4 (936.8 to 2132.5) | 1792.7 (1311.6 to 2450.4) | 1042.8 (620.3 to 1753.1) | 1270.3 (888.8 to 1815.5) |
| SARS-CoV-2 D614G Antibody: Day 1 | 2052.1 (1472.4 to 2860.0) | 2176.0 (1546.4 to 3062.0) | 2362.5 (1525.7 to 3658.3) | 2578.4 (1482.4 to 4484.8) | 2992.6 (2118.7 to 4226.9) | 2091.1 (1408.0 to 3105.7) | 3284.9 (2260.6 to 4773.3) | 2909.8 (2255.8 to 3753.4) | 1548.5 (1057.5 to 2267.5) | 1756.8 (1185.2 to 2604.2) | 2328.9 (1776.8 to 3052.6) | 1994.9 (1476.1 to 2696.1) | 1553.2 (1011.9 to 2384.1) | 1575.1 (1051.1 to 2360.4) | 2056.3 (1471.1 to 2874.2) | 1391.3 (986.7 to 1961.7) | 1527.4 (1057.0 to 2207.2) |
| SARS-CoV-2 D614G Antibody: Day 29 | 9943.4 (7910.9 to 12498.1) | 12229.6 (9571.1 to 15626.7) | 9275.7 (6926.0 to 12422.7) | 10433.9 (7040.4 to 15463.1) | 7678.3 (6034.4 to 9770.0) | 8513.1 (6542.0 to 11078.0) | 10057.5 (7712.1 to 13116.1) | 8639.7 (7025.9 to 10624.1) | 7038.1 (5592.1 to 8858.0) | 10243.2 (8204.9 to 12787.7) | 7431.1 (6091.6 to 9065.1) | 7127.4 (5855.8 to 8675.1) | 6525.4 (4850.0 to 8779.4) | 6738.9 (5281.8 to 8597.8) | 7844.9 (6467.6 to 9515.4) | 7333.0 (5842.7 to 9203.4) | 6877.4 (5218.1 to 9064.5) |
| SARS-CoV-2 D614G Antibody: Day 181 | 3583.2 (2756.2 to 4658.4) | 5778.1 (4110.6 to 8121.9) | 4006.2 (2759.3 to 5816.7) | 3927.0 (2086.7 to 7390.1) | 3317.4 (2397.5 to 4590.2) | 3877.3 (2667.2 to 5636.2) | 5622.0 (3718.2 to 8500.5) | 3889.4 (2807.8 to 5387.6) | 3296.0 (2452.4 to 4429.8) | 4324.3 (3256.8 to 5741.6) | 3292.4 (2601.5 to 4166.7) | 3008.6 (2336.9 to 3873.5) | 2633.9 (1532.5 to 4527.0) | 2743.1 (1976.1 to 3807.9) | 2904.4 (2145.9 to 3931.1) | 1908.1 (1316.1 to 2766.3) | 2386.0 (1676.1 to 3396.6) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 10 and ULOQ = 640 for Influenza A H1N1 and Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 320 for Influenza B/Victoria, and LLOQ = 10 and ULOQ = 640 for Influenza B/Yamagata antibody. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
| ratio | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody: Day 29 | 1.6 (1.2 to 2.0) | 1.8 (1.5 to 2.2) | 2.0 (1.7 to 2.3) | 2.7 (2.0 to 3.6) | 1.6 (1.4 to 2.0) | 2.5 (1.8 to 3.6) | 1.9 (1.5 to 2.4) | 2.6 (2.1 to 3.4) | 2.1 (1.6 to 2.8) | 2.2 (1.7 to 2.9) | 2.4 (1.8 to 3.2) | 2.4 (1.8 to 3.0) | 2.8 (2.1 to 3.9) | 2.4 (1.8 to 3.3) | 2.1 (1.6 to 2.7) | 2.3 (1.8 to 3.0) | 3.4 (2.5 to 4.5) | 2.4 (1.8 to 3.3) | 2.6 (1.7 to 3.8) | 2.6 (2.0 to 3.3) |
| Influenza A H1N1 Antibody: Day 181 | 2.1 (1.6 to 2.8) | 1.8 (1.3 to 2.4) | 1.8 (1.4 to 2.2) | 2.6 (1.6 to 4.2) | 1.9 (1.5 to 2.3) | 3.6 (2.6 to 5.0) | 2.4 (1.8 to 3.2) | 2.7 (2.0 to 3.7) | 2.6 (1.9 to 3.7) | 2.4 (1.9 to 3.2) | 2.5 (1.8 to 3.4) | 2.4 (1.9 to 3.1) | 3.2 (2.6 to 4.1) | 3.0 (2.2 to 4.1) | 2.3 (1.8 to 3.1) | 3.0 (2.1 to 4.3) | 3.3 (2.5 to 4.3) | 2.3 (1.7 to 3.1) | 2.3 (1.6 to 3.3) | 2.7 (2.0 to 3.6) |
| Influenza A H3N2 Antibody: Day 29 | 1.8 (1.4 to 2.3) | 2.0 (1.6 to 2.5) | 2.3 (1.8 to 2.8) | 3.7 (2.8 to 4.8) | 2.1 (1.7 to 2.6) | 3.8 (2.5 to 5.6) | 2.2 (1.8 to 2.8) | 2.8 (2.1 to 3.6) | 2.4 (1.7 to 3.4) | 3.1 (2.4 to 3.9) | 2.3 (1.8 to 3.0) | 2.3 (1.8 to 2.9) | 2.7 (2.1 to 3.5) | 2.7 (2.0 to 3.7) | 2.4 (1.8 to 3.3) | 2.9 (2.2 to 3.8) | 3.6 (2.6 to 5.0) | 2.5 (1.8 to 3.5) | 2.7 (1.9 to 3.8) | 3.3 (2.6 to 4.2) |
| Influenza A H3N2 Antibody: Day 181 | 2.5 (1.8 to 3.4) | 2.2 (1.6 to 2.9) | 3.2 (2.4 to 4.2) | 4.6 (3.1 to 6.8) | 2.9 (2.3 to 3.5) | 5.7 (3.4 to 9.5) | 3.2 (2.4 to 4.4) | 3.2 (2.3 to 4.3) | 2.7 (1.9 to 3.9) | 3.9 (3.0 to 5.0) | 3.0 (2.3 to 3.9) | 2.6 (1.9 to 3.4) | 3.2 (2.3 to 4.5) | 3.5 (2.5 to 4.8) | 3.5 (2.4 to 5.0) | 4.3 (2.9 to 6.4) | 3.8 (2.6 to 5.8) | 3.2 (2.3 to 4.3) | 3.3 (2.4 to 4.4) | 3.9 (2.8 to 5.5) |
| Influenza B/Victoria-lineage Antibody: Day 29 | 1.8 (1.3 to 2.5) | 2.2 (1.6 to 2.9) | 1.9 (1.5 to 2.4) | 3.3 (2.4 to 4.6) | 1.9 (1.6 to 2.4) | 2.5 (1.6 to 3.7) | 2.0 (1.7 to 2.4) | 2.9 (2.2 to 3.8) | 3.3 (2.3 to 4.7) | 2.5 (1.9 to 3.3) | 2.4 (1.8 to 3.2) | 1.9 (1.5 to 2.3) | 2.7 (2.1 to 3.4) | 2.1 (1.8 to 2.5) | 2.5 (1.8 to 3.4) | 2.6 (1.9 to 3.6) | 2.2 (1.7 to 2.8) | 3.1 (2.4 to 3.9) | 2.7 (2.0 to 3.8) | 2.4 (1.9 to 3.0) |
| Influenza B/Victoria-lineage Antibody: Day 181 | 2.9 (2.1 to 4.0) | 2.4 (1.7 to 3.4) | 2.1 (1.7 to 2.7) | 2.9 (2.0 to 4.3) | 1.9 (1.5 to 2.3) | 3.2 (2.1 to 5.0) | 2.3 (1.8 to 2.8) | 2.4 (1.7 to 3.4) | 4.0 (2.7 to 5.8) | 2.9 (2.2 to 3.9) | 3.1 (2.3 to 4.2) | 2.2 (1.6 to 2.9) | 3.4 (2.6 to 4.6) | 3.1 (2.3 to 4.0) | 3.6 (2.7 to 4.7) | 3.0 (1.8 to 5.0) | 2.5 (1.8 to 3.4) | 2.6 (2.1 to 3.2) | 3.1 (2.0 to 4.6) | 2.9 (2.1 to 4.0) |
| Influenza B/Yamagata-lineage Antibody: Day 29 | 1.5 (1.2 to 1.9) | 1.9 (1.5 to 2.6) | 1.6 (1.3 to 1.9) | 2.0 (1.6 to 2.6) | 1.4 (1.2 to 1.6) | 1.6 (1.2 to 2.1) | 1.5 (1.2 to 1.8) | 1.8 (1.5 to 2.2) | 1.7 (1.2 to 2.2) | 1.6 (1.3 to 1.9) | 1.9 (1.5 to 2.5) | 1.8 (1.5 to 2.1) | 2.1 (1.6 to 2.7) | 1.9 (1.5 to 2.4) | 2.0 (1.6 to 2.6) | 1.8 (1.4 to 2.2) | 2.1 (1.7 to 2.6) | 2.1 (1.8 to 2.4) | 2.4 (1.8 to 3.3) | 1.9 (1.5 to 2.4) |
| Influenza B/Yamagata-lineage Antibody: Day 181 | 1.9 (1.3 to 2.7) | 1.8 (1.1 to 3.0) | 1.3 (0.8 to 2.2) | 2.0 (1.3 to 3.0) | 1.3 (1.0 to 1.6) | 1.7 (1.0 to 2.9) | 1.2 (0.9 to 1.7) | 1.6 (1.0 to 2.7) | 2.0 (1.3 to 3.3) | 1.4 (1.0 to 1.9) | 1.1 (0.8 to 1.4) | 0.9 (0.7 to 1.3) | 1.4 (1.0 to 1.9) | 1.3 (0.9 to 1.8) | 1.4 (1.0 to 1.9) | 0.9 (0.7 to 1.3) | 1.5 (1.1 to 2.1) | 1.1 (0.8 to 1.6) | 1.2 (0.9 to 1.8) | 1.1 (0.8 to 1.5) |
SARS-CoV-2 strain included BA.4/5 and D614G antibody. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 53 and ULOQ = 71376 for SARS-CoV-2 BA.4/5 antibody and LLOQ = 74.1 and ULOQ = 184317 for SARS-CoV-2 D614G antibody. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
| ratio | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 BA.4/5 Antibody: Day 29 | 7.3 (5.0 to 10.9) | 10.0 (7.0 to 14.2) | 7.5 (5.0 to 11.2) | 9.6 (6.5 to 14.4) | 5.7 (4.1 to 7.9) | 6.8 (4.8 to 9.7) | 5.6 (3.7 to 8.5) | 4.7 (3.3 to 6.7) | 6.9 (4.7 to 10.0) | 10.9 (7.5 to 15.9) | 6.1 (4.2 to 9.0) | 6.9 (5.1 to 9.5) | 7.4 (4.9 to 11.1) | 7.3 (5.1 to 10.5) | 8.4 (5.9 to 11.8) | 10.3 (6.7 to 16.0) | 6.9 (4.6 to 10.4) |
| SARS-CoV-2 BA.4/5 Antibody: Day 181 | 2.5 (1.7 to 3.6) | 4.1 (2.7 to 6.3) | 3.2 (2.1 to 5.0) | 4.4 (2.3 to 8.4) | 2.6 (1.8 to 3.8) | 2.4 (1.6 to 3.8) | 1.9 (1.1 to 3.2) | 1.7 (1.1 to 2.5) | 3.5 (2.2 to 5.5) | 4.4 (3.1 to 6.4) | 2.8 (1.9 to 4.1) | 2.7 (1.9 to 3.9) | 2.7 (1.5 to 4.6) | 3.1 (2.1 to 4.6) | 3.5 (2.4 to 5.0) | 3.6 (2.4 to 5.3) | 2.9 (2.0 to 4.3) |
| SARS-CoV-2 D614G Antibody: Day 29 | 4.8 (3.6 to 6.5) | 5.6 (4.1 to 7.7) | 4.2 (2.9 to 6.0) | 4.0 (2.9 to 5.6) | 2.5 (1.9 to 3.4) | 4.1 (2.9 to 5.7) | 3.1 (2.2 to 4.2) | 3.0 (2.4 to 3.7) | 4.5 (3.4 to 6.2) | 5.8 (4.0 to 8.5) | 3.2 (2.4 to 4.2) | 3.6 (2.7 to 4.7) | 4.2 (3.1 to 5.7) | 4.3 (3.1 to 5.9) | 3.8 (2.9 to 5.1) | 5.3 (3.8 to 7.3) | 4.5 (3.2 to 6.3) |
| SARS-CoV-2 D614G Antibody: Day 181 | 1.7 (1.3 to 2.3) | 2.5 (1.7 to 3.8) | 1.7 (1.1 to 2.4) | 1.6 (1.0 to 2.8) | 1.2 (0.9 to 1.6) | 1.7 (1.2 to 2.4) | 1.6 (1.1 to 2.4) | 1.4 (1.1 to 1.7) | 2.0 (1.3 to 2.9) | 2.5 (1.8 to 3.5) | 1.5 (1.2 to 1.8) | 1.5 (1.1 to 2.1) | 1.4 (1.1 to 1.9) | 1.7 (1.3 to 2.3) | 1.4 (1.0 to 1.9) | 1.5 (1.2 to 2.0) | 1.7 (1.2 to 2.4) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \< 1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post vaccination HAI antibody titer. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
| percentage of participants | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody: Day 29 | 11.8 (4.4 to 23.9) | 14.0 (5.8 to 26.7) | 18.4 (8.8 to 32.0) | 28.9 (16.4 to 44.3) | 12.0 (4.5 to 24.3) | 33.3 (17.3 to 52.8) | 20.8 (10.8 to 34.1) | 34.0 (20.9 to 49.3) | 19.4 (7.5 to 37.5) | 18.0 (8.6 to 31.4) | 30.0 (17.9 to 44.6) | 27.7 (15.6 to 42.6) | 36.5 (23.6 to 51.0) | 30.0 (17.9 to 44.6) | 20.8 (10.8 to 34.1) | 19.4 (8.2 to 36.0) | 48.0 (33.7 to 62.6) | 30.8 (18.7 to 45.1) | 29.7 (15.9 to 47.0) | 37.3 (24.1 to 51.9) |
| Influenza A H1N1 Antibody: Day 181 | 28.2 (15.0 to 44.9) | 16.7 (6.4 to 32.8) | 16.1 (5.5 to 33.7) | 30.6 (16.3 to 48.1) | 23.3 (11.8 to 38.6) | 50.0 (28.2 to 71.8) | 27.3 (15.0 to 42.8) | 32.4 (18.0 to 49.8) | 36.0 (18.0 to 57.5) | 21.4 (10.3 to 36.8) | 31.1 (18.2 to 46.6) | 33.3 (19.1 to 50.2) | 40.9 (26.3 to 56.8) | 40.9 (26.3 to 56.8) | 38.6 (24.4 to 54.5) | 36.0 (18.0 to 57.5) | 44.2 (29.1 to 60.1) | 29.2 (17.0 to 44.1) | 29.6 (13.8 to 50.2) | 37.8 (23.8 to 53.5) |
| Influenza A H3N2 Antibody: Day 29 | 15.7 (7.0 to 28.6) | 22.0 (11.5 to 36.0) | 22.4 (11.8 to 36.6) | 55.6 (40.0 to 70.4) | 26.0 (14.6 to 40.3) | 43.3 (25.5 to 62.6) | 22.6 (12.3 to 36.2) | 38.0 (24.7 to 52.8) | 25.8 (11.9 to 44.6) | 44.9 (30.7 to 59.8) | 32.0 (19.5 to 46.7) | 31.9 (19.1 to 47.1) | 40.4 (27.0 to 54.9) | 34.0 (21.2 to 48.8) | 24.5 (13.8 to 38.3) | 44.4 (27.9 to 61.9) | 44.0 (30.0 to 58.7) | 38.5 (25.3 to 53.0) | 35.1 (20.2 to 52.5) | 34.0 (21.2 to 48.8) |
| Influenza A H3N2 Antibody: Day 181 | 33.3 (19.1 to 50.2) | 25.0 (12.1 to 42.2) | 45.2 (27.3 to 64.0) | 61.1 (43.5 to 76.9) | 39.5 (25.0 to 55.6) | 63.6 (40.7 to 82.8) | 43.2 (28.3 to 59.0) | 50.0 (33.4 to 66.6) | 32.0 (14.9 to 53.5) | 51.2 (35.1 to 67.1) | 44.4 (29.6 to 60.0) | 30.8 (17.0 to 47.6) | 47.7 (32.5 to 63.3) | 38.6 (24.4 to 54.5) | 38.6 (24.4 to 54.5) | 44.0 (24.4 to 65.1) | 46.5 (31.2 to 62.3) | 52.1 (37.2 to 66.7) | 40.7 (22.4 to 61.2) | 52.3 (36.7 to 67.5) |
| Influenza B/Victoria-lineage Antibody: Day 29 | 21.6 (11.3 to 35.3) | 18.0 (8.6 to 31.4) | 22.4 (11.8 to 36.6) | 48.8 (33.3 to 64.5) | 16.0 (7.2 to 29.1) | 23.3 (9.9 to 42.3) | 24.5 (13.8 to 38.3) | 36.2 (22.7 to 51.5) | 41.9 (24.5 to 60.9) | 28.0 (16.2 to 42.5) | 34.0 (21.2 to 48.8) | 13.0 (4.9 to 26.3) | 38.5 (25.3 to 53.0) | 16.0 (7.2 to 29.1) | 34.0 (21.5 to 48.3) | 38.9 (23.1 to 56.5) | 28.0 (16.2 to 42.5) | 38.5 (25.3 to 53.0) | 38.9 (23.1 to 56.5) | 28.0 (16.2 to 42.5) |
| Influenza B/Victoria-lineage Antibody: Day 181 | 35.9 (21.2 to 52.8) | 27.8 (14.2 to 45.2) | 25.8 (11.9 to 44.6) | 37.1 (21.5 to 55.1) | 18.6 (8.4 to 33.4) | 50.0 (28.2 to 71.8) | 20.5 (9.8 to 35.3) | 32.4 (18.0 to 49.8) | 60.0 (38.7 to 78.9) | 33.3 (19.6 to 49.5) | 48.9 (33.7 to 64.2) | 31.6 (17.5 to 48.7) | 43.2 (28.3 to 59.0) | 47.7 (32.5 to 63.3) | 45.5 (30.4 to 61.2) | 32.0 (14.9 to 53.5) | 32.6 (19.1 to 48.5) | 35.4 (22.2 to 50.5) | 48.1 (28.7 to 68.1) | 45.5 (30.4 to 61.2) |
| Influenza B/Yamagata-lineage Antibody: Day 29 | 9.8 (3.3 to 21.4) | 18.0 (8.6 to 31.4) | 12.2 (4.6 to 24.8) | 28.9 (16.4 to 44.3) | 2.0 (0.1 to 10.6) | 13.3 (3.8 to 30.7) | 7.5 (2.1 to 18.2) | 16.7 (7.5 to 30.2) | 16.1 (5.5 to 33.7) | 6.0 (1.3 to 16.5) | 24.0 (13.1 to 38.2) | 12.8 (4.8 to 25.7) | 23.1 (12.5 to 36.8) | 20.0 (10.0 to 33.7) | 21.2 (11.1 to 34.7) | 19.4 (8.2 to 36.0) | 20.0 (10.0 to 33.7) | 17.3 (8.2 to 30.3) | 32.4 (18.0 to 49.8) | 16.0 (7.2 to 29.1) |
| Influenza B/Yamagata-lineage Antibody: Day 181 | 28.2 (15.0 to 44.9) | 33.3 (18.6 to 51.0) | 19.4 (7.5 to 37.5) | 36.1 (20.8 to 53.8) | 9.3 (2.6 to 22.1) | 27.3 (10.7 to 50.2) | 15.9 (6.6 to 30.1) | 23.7 (11.4 to 40.2) | 29.2 (12.6 to 51.1) | 19.0 (8.6 to 34.1) | 8.9 (2.5 to 21.2) | 12.8 (4.3 to 27.4) | 18.2 (8.2 to 32.7) | 20.9 (10.0 to 36.0) | 15.9 (6.6 to 30.1) | 0 (0.0 to 13.7) | 16.3 (6.8 to 30.7) | 14.6 (6.1 to 27.8) | 14.8 (4.2 to 33.7) | 11.4 (3.8 to 24.6) |
SARS-CoV-2 strain included BA.4/5 and D614G antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 x LLOQ if baseline nAb level was \<LLOQ, or ≥4 fold rise if baseline nAb level was ≥LLOQ. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
| percentage of participants | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 BA.4/5 Antibody: Day 29 | 62.7 (48.1 to 75.9) | 69.4 (54.6 to 81.7) | 68.0 (53.3 to 80.5) | 75.9 (56.5 to 89.7) | 56.9 (45.1 to 73.0) | 62.7 (48.1 to 75.9) | 58.1 (39.1 to 75.5) | 44.0 (30.0 to 58.7) | 60.0 (45.2 to 73.6) | 76.5 (62.5 to 87.2) | 51.0 (36.6 to 65.2) | 62.3 (47.9 to 75.5) | 58.3 (40.8 to 74.5) | 60.0 (45.2 to 73.6) | 65.4 (50.9 to 78.0) | 68.4 (51.3 to 82.5) | 68.0 (53.3 to 80.5) |
| SARS-CoV-2 BA.4/5 Antibody: Day 181 | 37.8 (23.8 to 53.5) | 44.7 (28.6 to 61.7) | 41.9 (27.0 to 57.9) | 50.0 (28.2 to 71.8) | 41.9 (27.0 to 57.9) | 28.2 (15.0 to 44.9) | 20.0 (6.8 to 40.7) | 16.7 (7.0 to 31.4) | 40.9 (26.3 to 56.8) | 53.2 (38.1 to 67.9) | 29.5 (16.8 to 45.2) | 31.8 (18.6 to 47.6) | 32.0 (14.9 to 53.5) | 34.9 (21.0 to 50.9) | 39.6 (25.8 to 54.7) | 42.9 (24.5 to 62.8) | 35.6 (21.9 to 51.2) |
| SARS-CoV-2 D614G Antibody: Day 29 | 43.1 (29.3 to 57.8) | 57.1 (42.2 to 71.2) | 37.5 (24.0 to 52.6) | 56.7 (37.4 to 74.5) | 21.2 (11.1 to 34.7) | 43.1 (29.3 to 57.8) | 25.8 (11.9 to 44.6) | 32.0 (19.5 to 46.7) | 42.0 (28.2 to 56.8) | 50.9 (36.8 to 64.9) | 33.3 (20.8 to 47.9) | 39.6 (26.5 to 54.0) | 41.7 (25.5 to 59.2) | 42.0 (28.2 to 56.8) | 48.1 (34.0 to 62.4) | 57.9 (40.8 to 73.7) | 42.0 (28.2 to 56.8) |
| SARS-CoV-2 D614G Antibody: Day 181 | 17.8 (8.0 to 32.1) | 31.6 (17.5 to 48.7) | 18.6 (8.4 to 33.4) | 18.2 (5.2 to 40.3) | 7.0 (1.5 to 19.1) | 17.9 (7.5 to 33.5) | 12.0 (2.5 to 31.2) | 7.1 (1.5 to 19.5) | 22.7 (11.5 to 37.8) | 34.0 (20.9 to 49.3) | 9.1 (2.5 to 21.7) | 11.4 (3.8 to 24.6) | 8.0 (1.0 to 26.0) | 23.3 (11.8 to 38.6) | 12.5 (4.7 to 25.2) | 3.6 (0.1 to 18.3) | 15.9 (6.6 to 30.1) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
| titer | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody: Day 1 | 30.4 (20.3 to 45.4) | 30.1 (20.7 to 43.9) | 35.1 (24.0 to 51.3) | 41.8 (31.5 to 64.1) | 44.9 (31.5 to 64.1) | 40.6 (29.6 to 55.7) | 49.9 (33.3 to 74.8) | 45.5 (32.6 to 63.5) | 32.7 (22.9 to 46.8) | 31.4 (21.0 to 46.9) | 37.1 (26.7 to 51.6) |
| Influenza A H1N1 Antibody: Day 181 | 81.6 (57.6 to 115.8) | 91.3 (65.4 to 127.6) | 108.4 (74.6 to 157.5) | 95.1 (65.9 to 137.1) | 93.1 (63.1 to 137.4) | 119.9 (87.7 to 163.9) | 111.9 (72.1 to 173.6) | 76.4 (52.4 to 111.4) | 108.4 (78.2 to 150.2) | 82.8 (60.6 to 113.2) | 101.5 (73.1 to 141.1) |
| Influenza A H3N2 Antibody: Day 1 | 28.8 (21.3 to 38.8) | 36.5 (24.3 to 54.7) | 46.0 (31.9 to 66.3) | 37.2 (27.8 to 49.8) | 36.8 (28.1 to 48.3) | 46.4 (33.2 to 64.8) | 39.6 (28.9 to 54.4) | 36.6 (26.8 to 50.0) | 35.2 (25.7 to 48.3) | 42.1 (30.5 to 58.3) | 30.2 (22.9 to 39.7) |
| Influenza A H3N2 Antibody: Day 181 | 50.9 (37.1 to 69.8) | 65.2 (45.5 to 93.5) | 100.7 (72.9 to 139.2) | 64.1 (46.3 to 88.8) | 52.6 (38.2 to 72.5) | 89.8 (62.2 to 129.6) | 61.7 (43.7 to 87.0) | 49.3 (35.6 to 68.3) | 63.0 (45.5 to 87.3) | 82.9 (57.6 to 119.2) | 52.4 (37.7 to 72.9) |
| Influenza B/Victoria-lineage Antibody: Day 1 | 49.8 (38.6 to 64.2) | 41.0 (31.7 to 53.0) | 60.4 (49.9 to 73.1) | 52.6 (40.7 to 68.0) | 64.6 (49.0 to 85.0) | 62.3 (49.1 to 79.0) | 50.8 (39.0 to 66.2) | 66.1 (49.1 to 89.0) | 53.6 (41.1 to 69.8) | 49.3 (38.3 to 63.5) | 48.7 (37.4 to 63.5) |
| Influenza B/Victoria-lineage Antibody: Day 181 | 54.2 (39.7 to 74.1) | 55.4 (42.4 to 72.5) | 64.9 (47.9 to 87.9) | 56.5 (43.0 to 74.3) | 73.0 (54.6 to 97.4) | 69.9 (51.9 to 94.0) | 71.0 (53.2 to 94.8) | 62.5 (46.7 to 83.7) | 56.0 (44.5 to 70.4) | 62.0 (48.4 to 79.4) | 56.6 (44.8 to 71.4) |
| Influenza B/Yamagata-lineage Antibody: Day 1 | 80.8 (60.1 to 108.5) | 54.5 (40.8 to 72.9) | 84.7 (63.7 to 112.6) | 63.0 (47.2 to 83.9) | 70.1 (54.7 to 89.8) | 69.7 (53.6 to 90.5) | 69.4 (52.1 to 92.3) | 72.1 (53.8 to 96.6) | 73.6 (52.3 to 103.6) | 67.6 (49.9 to 91.5) | 63.0 (49.6 to 80.0) |
| Influenza B/Yamagata-lineage Antibody: Day 181 | 110.8 (82.9 to 148.0) | 92.3 (71.4 to 119.2) | 108.5 (78.7 to 149.4) | 68.5 (50.7 to 92.7) | 70.8 (54.7 to 91.6) | 80.7 (60.9 to 107.0) | 82.6 (59.1 to 115.5) | 60.8 (45.1 to 82.1) | 73.3 (54.0 to 99.6) | 84.7 (63.4 to 113.3) | 63.0 (46.1 to 86.1) |
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 arbitrary units (AU)/milliliter (mL) for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM concentration, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.
| AU/mL | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 Omicron XBB.1.5 Antibody: Day 1 | 292.2 (197.1 to 433.1) | 214.1 (145.3 to 315.4) | 128.8 (82.4 to 201.3) | 168.1 (110.3 to 256.1) | 198.5 (121.2 to 325.1) | 307.8 (194.8 to 486.4) | 151.5 (96.2 to 238.6) | 212.0 (140.8 to 319.2) | 127.6 (81.4 to 200.1) | 136.2 (92.0 to 201.7) |
| SARS-CoV-2 Omicron XBB.1.5 Antibody: Day 181 | 906.7 (678.5 to 1211.6) | 998.7 (640.6 to 1557.2) | 377.8 (258.0 to 553.4) | 562.2 (364.2 to 867.8) | 629.8 (419.3 to 946.0) | 809.5 (555.1 to 1180.3) | 349.0 (225.7 to 539.8) | 642.9 (445.3 to 928.2) | 682.7 (429.1 to 1086.2) | 472 (307.2 to 725.3) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ replaced by 0.5 \* LLOQ. Values greater than ULOQ converted to ULOQ. LLOQ= 10, ULOQ= 3620 for Influenza A H1N1, LLOQ= 10, ULOQ= 5120 for Influenza A H3N2, LLOQ= 10, ULOQ= 1356 for Influenza B/Victoria-lineage, and LLOQ= 10, ULOQ= 1280 for Influenza B/Yamagata-lineage. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
| ratio | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 2.9 (2.0 to 4.2) | 3.2 (2.3 to 4.4) | 3.1 (2.2 to 4.3) | 2.3 (1.8 to 2.8) | 2.1 (1.5 to 2.9) | 2.9 (2.2 to 3.9) | 2.3 (1.7 to 3.2) | 1.7 (1.2 to 2.4) | 3.7 (2.4 to 5.6) | 2.8 (2.0 to 4.1) | 3.0 (2.2 to 4.1) |
| Influenza A H3N2 Antibody | 2.0 (1.5 to 2.6) | 1.9 (1.5 to 2.6) | 2.1 (1.5 to 2.8) | 1.7 (1.3 to 2.2) | 1.4 (1.0 to 1.8) | 2.0 (1.6 to 2.6) | 1.4 (1.0 to 2.0) | 1.4 (1.1 to 1.7) | 2.0 (1.6 to 2.6) | 1.8 (1.4 to 2.5) | 1.8 (1.4 to 2.5) |
| Influenza B/Victoria-lineage Antibody | 1.2 (0.9 to 1.6) | 1.4 (1.1 to 1.9) | 1.1 (0.9 to 1.5) | 1.1 (0.8 to 1.4) | 1.1 (0.8 to 1.5) | 1.2 (0.9 to 1.5) | 1.4 (1.1 to 1.8) | 1.0 (0.7 to 1.3) | 1.2 (0.9 to 1.5) | 1.3 (1.0 to 1.7) | 1.2 (0.9 to 1.5) |
| Influenza B/Yamagata-lineage Antibody | 1.3 (1.1 to 1.6) | 1.6 (1.3 to 1.9) | 1.3 (1.0 to 1.6) | 1.1 (0.9 to 1.4) | 1.0 (0.8 to 1.3) | 1.2 (1.0 to 1.4) | 1.2 (1.0 to 1.6) | 0.9 (0.7 to 1.0) | 1.2 (0.9 to 1.6) | 1.2 (1.0 to 1.6) | 1.1 (0.8 to 1.3) |
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.
| ratio | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part 2: GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA | 3.3 (2.2 to 4.8) | 4.5 (2.7 to 7.7) | 2.8 (1.8 to 4.5) | 3.7 (2.2 to 6.2) | 3.4 (2.3 to 5.1) | 2.3 (1.5 to 3.5) | 2.5 (1.6 to 4.0) | 2.9 (1.9 to 4.5) | 4.7 (2.7 to 8.1) | 3.9 (2.8 to 5.5) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \<1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer. PP Set included all randomized participants who received the study intervention, complied with the injection schedule, complied with the timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected the immune response.
| percentage of participants | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 45.5 (28.1 to 63.6) | 50.0 (32.4 to 67.6) | 36.4 (20.4 to 54.9) | 22.2 (10.1 to 39.2) | 23.5 (10.7 to 41.2) | 36.1 (20.8 to 53.8) | 25.0 (11.5 to 43.4) | 26.3 (13.4 to 43.1) | 40.6 (23.7 to 59.4) | 40.0 (22.7 to 59.4) | 43.8 (26.4 to 62.3) |
| Influenza A H3N2 Antibody | 30.3 (15.6 to 48.7) | 29.4 (15.1 to 47.5) | 24.2 (11.1 to 42.3) | 19.4 (8.2 to 36.0) | 11.8 (3.3 to 27.5) | 25.0 (12.1 to 42.2) | 15.6 (5.3 to 32.8) | 10.5 (2.9 to 24.8) | 34.4 (18.6 to 53.2) | 26.7 (12.3 to 45.9) | 28.1 (13.7 to 46.7) |
| Influenza B/Victoria-lineage Antibody | 12.1 (3.4 to 28.2) | 8.8 (1.9 to 23.7) | 9.1 (1.9 to 24.3) | 5.6 (0.7 to 18.7) | 8.8 (1.9 to 23.7) | 5.6 (0.7 to 18.7) | 9.4 (2.0 to 25.0) | 10.5 (2.9 to 24.8) | 12.5 (3.5 to 29.0) | 10.0 (2.1 to 26.5) | 6.3 (0.8 to 20.8) |
| Influenza B/Yamagata-lineage Antibody | 9.1 (1.9 to 24.3) | 8.8 (1.9 to 23.7) | 6.1 (0.7 to 20.2) | 5.6 (0.7 to 18.7) | 2.9 (0.1 to 15.3) | 2.8 (0.1 to 14.5) | 9.4 (2.0 to 25.0) | 2.6 (0.1 to 13.8) | 6.3 (0.8 to 20.8) | 6.7 (0.8 to 20.8) | 0 (0.0 to 10.9) |
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 \* LLOQ if Baseline nAb level was \< LLOQ, or ≥4-fold rise if Baseline nAb level was ≥ LLOQ. PP Set included all randomized participants who received the study intervention, complied with the injection schedule, complied with the timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected the immune response.
| percentage of participants | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA | 40.5 (24.8 to 57.9) | 43.3 (25.5 to 62.6) | 36.1 (20.8 to 53.8) | 32.4 (17.4 to 50.5) | 37.1 (21.5 to 55.1) | 25.0 (11.5 to 43.4) | 31.6 (17.5 to 48.7) | 28.1 (13.7 to 46.7) | 50.0 (31.3 to 68.7) | 50.0 (31.9 to 68.1) |
Collected over All-cause mortality, SAEs, AESIs, MAAEs, and AEs leading to study discontinuation were collected up to Day 181. Other (non-serious) adverse events were collected from the time of injection through 28 days after the injection, unless they met the criteria for AESIs, MAAEs, or AEs led to study discontinuation.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Cohort A12: Influenza Vaccine 1 | 0/54 (0%) | 2/54 (3.7%) | 1/54 (1.9%) |
| Part 1 Cohort A13: Influenza Vaccine 2 | 0/53 (0%) | 2/53 (3.8%) | 3/53 (5.7%) |
| Part 1 Cohort A11: Investigational Influenza Vaccine 2 | 0/54 (0%) | 1/54 (1.9%) | 4/54 (7.4%) |
| Part 1 Cohort A8: Investigational Influenza Vaccine 1 | 0/53 (0%) | 1/51 (2%) | 3/51 (5.9%) |
| Part 1 Cohort A10: COVID-19 Vaccine 1 | 0/54 (0%) | 2/54 (3.7%) | 1/54 (1.9%) |
| Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | 0/52 (0%) | 1/52 (1.9%) | 6/52 (11.5%) |
| Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | 0/52 (0%) | 2/51 (3.9%) | 3/51 (5.9%) |
| Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | 0/33 (0%) | 0/33 (0%) | 2/33 (6.1%) |
| Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | 0/54 (0%) | 1/55 (1.8%) | 0/55 (0%) |
| Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | 0/54 (0%) | 1/53 (1.9%) | 6/53 (11.3%) |
| Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | 0/33 (0%) | 1/33 (3%) | 0/33 (0%) |
| Part 1 Cohort A7: mRNA-1083.3 | 0/53 (0%) | 1/53 (1.9%) | 0/53 (0%) |
| Part 1 Cohort B12: Influenza Vaccine 1 | 0/52 (0%) | 1/52 (1.9%) | 1/52 (1.9%) |
| Part 1 Cohort B11: Investigational Influenza Vaccine 2 | 0/56 (0%) | 2/55 (3.6%) | 3/55 (5.5%) |
| Part 1 Cohort B8: Investigational Influenza Vaccine 1 | 0/56 (0%) | 1/55 (1.8%) | 2/55 (3.6%) |
| Part 1 Cohort B10: COVID-19 Vaccine 1 | 0/56 (0%) | 0/53 (0%) | 2/53 (3.8%) |
| Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | 0/55 (0%) | 0/55 (0%) | 2/55 (3.6%) |
| Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | 0/56 (0%) | 1/56 (1.8%) | 7/56 (12.5%) |
| Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | 0/56 (0%) | 0/55 (0%) | 1/55 (1.8%) |
| Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | 0/37 (0%) | 1/37 (2.7%) | 2/37 (5.4%) |
| Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | 0/55 (0%) | 1/56 (1.8%) | 4/56 (7.1%) |
| Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | 0/56 (0%) | 0/54 (0%) | 8/54 (14.8%) |
| Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | 0/38 (0%) | 1/38 (2.6%) | 5/38 (13.2%) |
| Part 1 Cohort B7: mRNA-1083.3 | 0/56 (0%) | 2/54 (3.7%) | 2/54 (3.7%) |
| Part 2: Influenza Vaccine 1 | 0/41 (0%) | 1/40 (2.5%) | 2/40 (5%) |
| Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | 0/40 (0%) | 1/39 (2.6%) | 0/39 (0%) |
| Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | 0/40 (0%) | 1/40 (2.5%) | 2/40 (5%) |
| Part 2: COVID-19 Vaccine 2 | 0/42 (0%) | 0/42 (0%) | 0/42 (0%) |
| Part 2: Investigational COVID-19 Vaccine 2 | 0/40 (0%) | 0/40 (0%) | 3/40 (7.5%) |
| Part 2: mRNA-1083 Composition 1 Dose Level 1 | 0/40 (0%) | 1/40 (2.5%) | 3/40 (7.5%) |
| Part 2: mRNA-1083 Composition 1 Dose Level 2 | 0/42 (0%) | 0/42 (0%) | 1/42 (2.4%) |
| Part 2: mRNA-1083 Composition 1 Dose Level 3 | 0/42 (0%) | 1/41 (2.4%) | 5/41 (12.2%) |
| Part 2: mRNA-1083 Composition 1 Dose Level 4 | 0/41 (0%) | 0/41 (0%) | 1/41 (2.4%) |
| Part 2: mRNA-1083 Composition 2 Dose Level 1 | 0/40 (0%) | 0/40 (0%) | 5/40 (12.5%) |
| Part 2: mRNA-1083 Composition 2 Dose Level 2 | 0/40 (0%) | 0/40 (0%) | 2/40 (5%) |
| Part 2: mRNA-1083 Composition 2 Dose Level 3 | 0/40 (0%) | 1/40 (2.5%) | 4/40 (10%) |
| Part 2: mRNA-1083 Composition 2 Dose Level 4 | 0/42 (0%) | 0/42 (0%) | 2/42 (4.8%) |
| Event | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/54 | 0/53 | 0/54 | 0/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 1/33 | 0/53 | 0/52 | 0/55 | 0/55 | 0/53 | 0/55 | 0/56 | 0/55 | 0/37 | 0/56 | 0/54 | 0/38 | 0/54 | 0/40 | 0/39 | 0/40 | 0/42 | 0/40 | 0/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 0/40 | 0/42 |
| Renal pseudoaneurysmRenal and urinary disorders | 0/54 | 0/53 | 0/54 | 0/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 0/33 | 0/53 | 0/52 | 0/55 | 0/55 | 0/53 | 0/55 | 0/56 | 0/55 | 1/37 | 0/56 | 0/54 | 0/38 | 0/54 | 0/40 | 0/39 | 0/40 | 0/42 | 0/40 | 0/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 0/40 | 0/42 |
| Intestinal obstructionGastrointestinal disorders | 0/54 | 0/53 | 0/54 | 0/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 0/33 | 0/53 | 0/52 | 0/55 | 0/55 | 0/53 | 0/55 | 0/56 | 0/55 | 0/37 | 0/56 | 0/54 | 1/38 | 0/54 | 0/40 | 0/39 | 0/40 | 0/42 | 0/40 | 0/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 0/40 | 0/42 |
| SepsisInfections and infestations | 0/54 | 0/53 | 0/54 | 0/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 0/33 | 0/53 | 0/52 | 0/55 | 0/55 | 0/53 | 0/55 | 0/56 | 0/55 | 0/37 | 0/56 | 0/54 | 0/38 | 0/54 | 0/40 | 1/39 | 0/40 | 0/42 | 0/40 | 0/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 0/40 | 0/42 |
| SeizureNervous system disorders | 0/54 | 0/53 | 0/54 | 0/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 0/33 | 0/53 | 0/52 | 0/55 | 1/55 | 0/53 | 0/55 | 0/56 | 0/55 | 0/37 | 0/56 | 0/54 | 0/38 | 0/54 | 0/40 | 1/39 | 0/40 | 0/42 | 0/40 | 1/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 0/40 | 0/42 |
| Coeliac artery compression syndromeGastrointestinal disorders | 0/54 | 0/53 | 0/54 | 0/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 0/33 | 0/53 | 0/52 | 0/55 | 0/55 | 0/53 | 0/55 | 0/56 | 0/55 | 0/37 | 0/56 | 0/54 | 0/38 | 0/54 | 0/40 | 1/39 | 0/40 | 0/42 | 0/40 | 0/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 0/40 | 0/42 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/54 | 0/53 | 0/54 | 0/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 0/33 | 0/53 | 0/52 | 0/55 | 0/55 | 0/53 | 0/55 | 0/56 | 0/55 | 0/37 | 0/56 | 0/54 | 0/38 | 0/54 | 0/40 | 1/39 | 0/40 | 0/42 | 0/40 | 0/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 0/40 | 0/42 |
| CellulitisInfections and infestations | 0/54 | 0/53 | 0/54 | 0/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 0/33 | 0/53 | 0/52 | 0/55 | 0/55 | 0/53 | 0/55 | 0/56 | 0/55 | 0/37 | 0/56 | 0/54 | 0/38 | 0/54 | 0/40 | 0/39 | 0/40 | 0/42 | 0/40 | 1/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 0/40 | 0/42 |
| Bipolar II disorderPsychiatric disorders | 0/54 | 0/53 | 0/54 | 0/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 0/33 | 0/53 | 0/52 | 0/55 | 0/55 | 0/53 | 0/55 | 0/56 | 0/55 | 0/37 | 0/56 | 0/54 | 0/38 | 0/54 | 1/40 | 0/39 | 0/40 | 0/42 | 0/40 | 0/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 0/40 | 0/42 |
| Major depressionPsychiatric disorders | 0/54 | 0/53 | 0/54 | 0/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 0/33 | 0/53 | 0/52 | 0/55 | 0/55 | 0/53 | 0/55 | 0/56 | 0/55 | 0/37 | 0/56 | 0/54 | 0/38 | 0/54 | 0/40 | 0/39 | 0/40 | 0/42 | 0/40 | 0/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 1/40 | 0/42 |
| Event | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/54 | 0/53 | 2/54 | 0/51 | 0/54 | 2/52 | 1/51 | 0/33 | 0/55 | 3/53 | 0/33 | 0/53 | 0/52 | 1/55 | 0/55 | 2/53 | 0/55 | 3/56 | 0/55 | 1/37 | 2/56 | 6/54 | 0/38 | 1/54 | 1/40 | 0/39 | 2/40 | 0/42 | 1/40 | 2/40 | 0/42 | 2/41 | 1/41 | 3/40 | 1/40 | 2/40 | 1/42 |
| COVID-19Infections and infestations | 0/54 | 0/53 | 0/54 | 0/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 0/33 | 0/53 | 0/52 | 0/55 | 0/55 | 0/53 | 0/55 | 0/56 | 0/55 | 0/37 | 0/56 | 0/54 | 0/38 | 0/54 | 1/40 | 0/39 | 0/40 | 0/42 | 2/40 | 1/40 | 1/42 | 3/41 | 0/41 | 2/40 | 1/40 | 1/40 | 1/42 |
| Urinary tract infectionInfections and infestations | 0/54 | 1/53 | 2/54 | 1/51 | 1/54 | 2/52 | 1/51 | 2/33 | 0/55 | 1/53 | 0/33 | 0/53 | 1/52 | 1/55 | 0/55 | 1/53 | 1/55 | 2/56 | 0/55 | 0/37 | 1/56 | 1/54 | 1/38 | 0/54 | 0/40 | 0/39 | 0/40 | 0/42 | 0/40 | 0/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 1/40 | 0/42 |
| Rhinovirus infectionInfections and infestations | 1/54 | 2/53 | 0/54 | 1/51 | 0/54 | 3/52 | 1/51 | 0/33 | 0/55 | 3/53 | 0/33 | 0/53 | 0/52 | 1/55 | 2/55 | 0/53 | 1/55 | 2/56 | 1/55 | 2/37 | 0/56 | 1/54 | 2/38 | 1/54 | 0/40 | 0/39 | 0/40 | 0/42 | 0/40 | 0/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 0/40 | 0/42 |
| PalpitationsCardiac disorders | 0/54 | 0/53 | 0/54 | 1/51 | 0/54 | 0/52 | 0/51 | 0/33 | 0/55 | 0/53 | 0/33 | 0/53 | 0/52 | 0/55 | 0/55 | 0/53 | 0/55 | 1/56 | 0/55 | 0/37 | 1/56 | 0/54 | 2/38 | 0/54 | 0/40 | 0/39 | 0/40 | 0/42 | 0/40 | 0/40 | 0/42 | 0/41 | 0/41 | 0/40 | 0/40 | 0/40 | 0/42 |
The FAS included all randomized participants who received the study intervention. Participants were analyzed according to the group to which they were randomized.
| Age, Categorical(Participants) | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 52 | 55 | 55 | 53 | 55 | 55 | 56 | 37 | 55 | 55 | 38 | 54 | 40 | 39 | 40 | 42 | 40 | 40 | 42 | 41 | 41 | 40 | 40 | 40 | 42 | 1147 |
| >=65 years | 54 | 53 | 54 | 51 | 54 | 52 | 51 | 33 | 54 | 54 | 33 | 53 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 596 |
| Sex: Female, Male(Participants) | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 32 | 30 | 29 | 29 | 33 | 30 | 27 | 16 | 30 | 30 | 14 | 28 | 32 | 23 | 31 | 29 | 28 | 28 | 31 | 17 | 33 | 31 | 24 | 30 | 23 | 20 | 24 | 18 | 15 | 22 | 21 | 22 | 18 | 23 | 25 | 22 | 23 | 941 |
| Male | 22 | 23 | 25 | 22 | 21 | 22 | 24 | 17 | 24 | 24 | 19 | 25 | 20 | 32 | 24 | 24 | 27 | 27 | 25 | 20 | 22 | 24 | 14 | 24 | 17 | 19 | 16 | 24 | 25 | 18 | 21 | 19 | 23 | 17 | 15 | 18 | 19 | 802 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 6 | 3 | 4 | 6 | 8 | 4 | 5 | 4 | 3 | 8 | 8 | 2 | 8 | 7 | 4 | 7 | 5 | 5 | 9 | 7 | 5 | 5 | 7 | 3 | 4 | 2 | 8 | 4 | 10 | 11 | 2 | 5 | 10 | 6 | 6 | 209 |
| Not Hispanic or Latino | 50 | 49 | 47 | 47 | 50 | 44 | 43 | 28 | 49 | 49 | 30 | 45 | 44 | 51 | 47 | 46 | 51 | 47 | 50 | 32 | 46 | 48 | 33 | 48 | 33 | 35 | 36 | 40 | 32 | 35 | 32 | 29 | 38 | 34 | 30 | 34 | 35 | 1517 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 17 |
| Race/Ethnicity, Customized(Participants) | Part 1 Cohort A12: Influenza Vaccine 1 | Part 1 Cohort A13: Influenza Vaccine 2 | Part 1 Cohort A11: Investigational Influenza Vaccine 2 | Part 1 Cohort A8: Investigational Influenza Vaccine 1 | Part 1 Cohort A10: COVID-19 Vaccine 1 | Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort A2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort A3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort A4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort A5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort A6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort A7: mRNA-1083.3 | Part 1 Cohort B12: Influenza Vaccine 1 | Part 1 Cohort B11: Investigational Influenza Vaccine 2 | Part 1 Cohort B8: Investigational Influenza Vaccine 1 | Part 1 Cohort B10: COVID-19 Vaccine 1 | Part 1 Cohort B9: Investigational COVID-19 Vaccine 1 | Part 1 Cohort B1: mRNA-1083.1 Dose Level 1 | Part 1 Cohort B2: mRNA-1083.1 Dose Level 2 | Part 1 Cohort B3: mRNA-1083.1 Dose Level 3 | Part 1 Cohort B4: mRNA-1083.2 Dose Level 1 | Part 1 Cohort B5: mRNA-1083.2 Dose Level 2 | Part 1 Cohort B6: mRNA-1083.2 Dose Level 3 | Part 1 Cohort B7: mRNA-1083.3 | Part 2: Influenza Vaccine 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 1 | Part 2: Investigational Influenza Vaccine 1 Dose Level 2 | Part 2: COVID-19 Vaccine 2 | Part 2: Investigational COVID-19 Vaccine 2 | Part 2: mRNA-1083 Composition 1 Dose Level 1 | Part 2: mRNA-1083 Composition 1 Dose Level 2 | Part 2: mRNA-1083 Composition 1 Dose Level 3 | Part 2: mRNA-1083 Composition 1 Dose Level 4 | Part 2: mRNA-1083 Composition 2 Dose Level 1 | Part 2: mRNA-1083 Composition 2 Dose Level 2 | Part 2: mRNA-1083 Composition 2 Dose Level 3 | Part 2: mRNA-1083 Composition 2 Dose Level 4 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Race — White | 48 | 47 | 46 | 44 | 44 | 43 | 46 | 28 | 45 | 50 | 27 | 45 | 38 | 39 | 43 | 36 | 37 | 36 | 37 | 30 | 41 | 39 | 22 | 37 | 29 | 26 | 25 | 26 | 25 | 29 | 26 | 24 | 24 | 22 | 22 | 22 | 29 | 1277 |
| Race — Black or African American | 6 | 5 | 8 | 6 | 9 | 7 | 5 | 5 | 5 | 4 | 6 | 6 | 13 | 12 | 7 | 14 | 12 | 11 | 16 | 3 | 11 | 11 | 14 | 14 | 7 | 7 | 12 | 10 | 7 | 6 | 10 | 10 | 9 | 13 | 7 | 13 | 9 | 330 |
| Race — Asian | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 2 | 4 | 2 | 3 | 4 | 2 | 3 | 0 | 4 | 1 | 2 | 4 | 6 | 3 | 5 | 4 | 3 | 4 | 5 | 6 | 3 | 7 | 3 | 3 | 90 |
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Race — Multiracial | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 14 |
| Race — Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 14 |
| Race — Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race — Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2023 to primary completion in Dec 2024, 19 months.
Results were first posted in Dec 2025, 1 year after primary completion.
Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 19 months is above that.
Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MRNA-1083